Sanofi, Regeneron expand antibody alliance in long-acting immunology programs for USD 1 billion upfront

• Sanofi expanded its global antibody alliance with Regeneron to add four next-generation, long-acting immunology antibody programs.
• Regeneron will receive USD 1 billion upfront, with up to USD 7 billion in development, regulatory, and commercial milestones.
• Companies will split development and commercialization costs, with future profits shared 50:50 globally.
• Regeneron will lead R&D; Sanofi will lead global commercialization; existing Dupixent profit-sharing terms remain unchanged.
• REGN20423 is in phase 1 for atopic dermatitis; three additional antibodies are expected to enter clinical studies in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010100PRIMZONEFULLFEED1001275651) on October 01, 2026, and is solely responsible for the information contained therein.